12:00 AM
Jan 19, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Mipomersen: Phase III started

The companies began a double-blind, placebo-controlled, U.S. and Canadian Phase III trial (MIPO3500108) to evaluate 200 mg of subcutaneous mipomersen given weekly in 75 patients who are on a maximally tolerated...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >